Top 5 Biotech Venture Capital Deals, H1 2010

The first half of 2010 has drawn to a close, so it's time to look back on the biggest biotech venture capital deals so far this year. At the halfway point the leader is Archimedes Pharma, and England-based developer that has raised $100 million to support the planned roll-out of PecFent, a fentanyl nasal spray designed to treat breakthrough cancer pain. Overall, the biotech industry has raised $2.1 billion in 238 deals through the end of June 2010, according to the National Venture Capital Association.

Archimedes Pharma $100M
Tesaro  $60M
Achaogen  $56M
NGM Biopharmaceuticals $51M
Neurotherapeutics Pharma

$43M

Read more on

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.